RCUS Stock Cash Flow Statements

Arcus Biosciences Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Arcus Biosciences Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31

cash flow from operating activities
net income	0	-112,000,000	-94,000,000	-92,000,000	-93,000,000	-4,000,000	-81,000,000	-71,000,000	-75,000,000	-80,000,000	-67,456,000	-64,919,000	-66,632,000	-67,993,000	279,368,000	-77,975,000	-75,970,000	-72,593,000	-51,853,000	1,822,000	-45,074,000	-27,753,000	-16,598,000	-22,352,000	-28,090,000	-17,670,000	-12,295,000	-10,811,000	-13,534,000	-12,954,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation expense	15,000,000	16,000,000	17,000,000	19,000,000	20,000,000	20,000,000	18,000,000	18,000,000	18,000,000	19,000,000	16,522,000	16,260,000	15,677,000	16,541,000	13,815,000	14,585,000	13,367,000	12,761,000	7,891,000	6,002,000	4,470,000	3,462,000	2,437,000	2,740,000	2,130,000	1,674,000	1,054,000	1,048,000	1,116,000	656,000
depreciation and amortization	2,000,000	3,000,000	3,000,000	2,000,000	2,000,000	3,000,000	3,000,000	1,000,000	2,000,000	2,000,000	1,478,000	1,560,000	1,505,000	1,457,000	1,260,000	963,000	820,000	800,000	778,000	742,000	787,000	842,000	856,000	886,000	883,000	953,000	947,000	974,000	915,000	828,000
noncash lease expense	1,000,000	2,000,000	2,000,000	1,000,000	2,000,000	2,000,000	2,000,000	2,000,000	2,000,000	2,000,000	1,951,000	2,049,000	2,024,000	1,976,000
impairment of long-lived assets				0	0	20,000,000
amortization of discounts on marketable securities	-3,000,000	-4,000,000	-6,000,000	-6,000,000	-7,000,000	-6,000,000
other items			1,000,000	1,000,000			0	1,000,000	0	1,000,000
changes in operating assets and liabilities:
receivable from collaboration partners	0	5,000,000	-4,000,000	12,000,000	7,000,000	13,000,000	0	11,000,000	-2,000,000	6,000,000	-11,809,000	7,045,000	-6,412,000	715,176,000	-17,224,000	704,000	3,660,000	-4,186,000	1,530,000	-2,357,000	122,000	-212,000
other assets			6,000,000	1,000,000	10,000,000	5,000,000	-2,000,000	-11,000,000	7,000,000	-8,000,000
accounts payable	8,000,000	3,000,000	5,000,000	-1,000,000	0	-1,000,000	2,000,000	6,000,000	-19,000,000	10,000,000	8,054,000	-12,156,000	3,964,000	8,138,000	651,000	-1,855,000	-11,291,000	7,722,000	6,107,000	-3,503,000	9,010,000	-2,342,000	1,820,000	472,000	-49,000	-517,000	960,000	-2,376,000	1,653,000	-306,000
deferred revenue	-160,000,000	-28,000,000	-42,000,000	67,000,000	-39,000,000	-42,000,000	-17,000,000	-32,000,000	6,000,000	-25,000,000	-33,655,000	-33,581,000	-26,759,000	-18,005,000	-339,501,000	-9,461,000	-9,461,000	-9,461,000	-9,511,000	191,390,000	-1,750,000	-1,750,000	-1,750,000	3,250,000	-1,750,000	-1,750,000	-1,562,000	3,709,000	-1,250,000	-1,250,000
other liabilities	5,000,000	-17,000,000	12,000,000	22,000,000	3,000,000	-12,000,000	-7,000,000	17,000,000	8,000,000	-21,000,000
net cash from operating activities	-133,000,000	-132,000,000	-100,000,000	26,000,000	-94,000,000	-2,000,000	-88,000,000	-63,000,000	-57,000,000	-98,000,000	-69,739,000	-80,959,000	-65,303,000	654,001,000	-62,103,000	-53,757,000	-73,995,000	-66,316,000	-49,880,000	216,265,000	-23,938,000	-31,277,000	-9,471,000	-27,399,000	-19,753,000	-16,839,000	-7,107,000	-11,765,000	-10,877,000	-13,247,000
capex	0	-1,000,000	-1,000,000	-1,000,000	0	-4,000,000	-6,000,000	-10,000,000	-5,000,000	-3,000,000	-380,000	-1,318,000	-1,514,000	-2,788,000	-8,506,000	-7,858,000	-6,073,000	-3,641,000	-1,519,000	-1,071,000	-256,000	-209,000	-196,000	-550,000	-551,000	-628,000	-258,000	-1,127,000	0	-359,000
free cash flows	-133,000,000	-133,000,000	-101,000,000	25,000,000	-94,000,000	-6,000,000	-94,000,000	-73,000,000	-62,000,000	-101,000,000	-70,119,000	-82,277,000	-66,817,000	651,213,000	-70,609,000	-61,615,000	-80,068,000	-69,957,000	-51,399,000	215,194,000	-24,194,000	-31,486,000	-9,667,000	-27,949,000	-20,304,000	-17,467,000	-7,365,000	-12,892,000	-10,877,000	-13,606,000
cash flow from investing activities
purchases of marketable securities	-161,000,000	-353,000,000	-172,000,000	-278,000,000	-206,000,000	-387,000,000	-115,000,000	-280,000,000	-239,000,000	-154,000,000
proceeds from maturities of marketable securities	255,000,000	360,000,000	203,000,000	242,000,000	262,000,000	222,000,000	145,000,000	295,000,000	258,000,000	284,000,000
proceeds from sales of marketable securities	43,000,000	26,000,000	21,000,000	8,000,000			4,000,000	6,000,000	12,000,000	2,000,000
purchases of property and equipment	0	-1,000,000	-1,000,000	-1,000,000	0	-4,000,000	-6,000,000	-10,000,000	-5,000,000	-3,000,000	-380,000	-1,318,000	-1,514,000	-2,788,000	-8,506,000	-7,858,000	-6,073,000	-3,641,000	-1,519,000	-1,071,000	-256,000	-209,000	-196,000	-550,000	-551,000	-628,000	-258,000	-1,127,000
net cash from investing activities	137,000,000	32,000,000	51,000,000	-29,000,000	63,000,000	-169,000,000	28,000,000	11,000,000	26,000,000	129,000,000	46,811,000	23,446,000	-215,197,000	-268,060,000	18,914,000	-88,611,000	3,003,000	62,826,000	-231,000	-387,119,000	-87,073,000	40,056,000	-12,104,000	30,364,000	26,673,000	14,279,000	2,511,000	-83,337,000	-16,123,000	-16,491,000
cash flow from financing activities
proceeds from issuance of common stock	0	142,000,000		0	0	228,000,000	0									0						643,000
proceeds from debt issuances			0
proceeds from issuance of common stock pursuant to equity award plans			3,000,000	2,000,000	3,000,000	1,000,000	3,000,000	1,000,000	3,000,000	1,000,000	6,195,000	2,531,000	4,346,000	9,928,000	6,671,000	1,318,000	2,237,000	1,885,000	1,682,000	270,000
payments of employee taxes related to net settlement of equity awards			-5,000,000	-1,000,000
net cash from financing activities	52,000,000	142,000,000	-2,000,000	48,000,000	2,000,000	229,000,000	3,000,000	6,000,000	23,000,000	1,000,000	11,195,000	2,531,000	4,346,000	14,928,000	11,671,000	1,318,000	2,231,000	222,120,000	1,677,000	107,518,000	328,870,000	610,000	520,000	-41,000	649,000	-5,000	771,000	-7,000	-1,118,000	129,428,000
net increase in cash, cash equivalents and restricted cash	56,000,000	42,000,000	-51,000,000	45,000,000	-29,000,000	58,000,000	-57,000,000	-46,000,000	-8,000,000	32,000,000	-11,733,000
cash, cash equivalents and restricted cash at beginning of period	0	153,000,000	0	0	0	130,000,000	0	0	0	209,000,000	81,000	0	0	150,919,000	0	0	0	173,618,000	0	0	0	58,140,000	0	0	0	71,267,000
cash, cash equivalents and restricted cash at end of period	56,000,000	195,000,000	-51,000,000	45,000,000	-29,000,000	188,000,000	-57,000,000	-46,000,000	-8,000,000	241,000,000	-11,652,000	-54,982,000	-276,154,000	551,788,000	-31,518,000	-141,050,000	-68,761,000	392,248,000	-48,434,000	-63,336,000	217,859,000	67,529,000	-21,055,000	2,924,000	7,569,000	68,702,000
non-cash investing and financing activities:
unpaid portion of property and equipment purchases included in accounts payable and other current liabilities						1,000,000	-4,000,000
impairment on right-of use assets
proceeds from issuance of common stock (228, 20 and — from a related party)
proceeds from sale of future royalties											5,000,000	0	0	5,000,000
supplemental disclosure of cash flow information
income taxes paid											257,000	0
interest paid
amortization of premiums (discounts) on marketable securities							-6,000,000	-5,000,000	-4,000,000	-4,000,000
purchases of in-process research and development											-500,000	0
collaboration reimbursements of in-process research and development from a related party											250,000
unpaid portion of other assets included in accrued research and development															-1,575,000
vesting of early exercised stock options and restricted stock												0	0	52,000	157,000				205,000	207,000	216,000	220,000	245,000	251,000	260,000	273,000	294,000	335,000
cash flows from operating activities
cash flows from investing activities
collaboration reimbursements of in-process research and development
cash flows from financing activities
proceeds from issuance of common stock to a related party
unpaid portion of property and equipment purchases included in accounts payable and accrued liabilities									4,000,000	4,000,000	1,665,000	718,000	-74,000	691,000	-3,609,000	-1,883,000	3,704,000	2,784,000	1,338,000	135,000	34,000	76,000	-21,000	-15,000	-332,000	380,000	33,000	-904,000
unpaid acquisition of in-process research and development														2,500,000
amortization of premiums on marketable securities
proceeds from issuance of common stock and rights to purchase additional shares
amortization of premiums on investments												-368,000	710,000	1,670,000	1,968,000	1,392,000	906,000	506,000	287,000	-10,000	-75,000	-248,000	-425,000	-633,000	-833,000	-747,000
acquired in-process research and development												-1,250,000	0	2,500,000
effective interest on liability for sale of future royalties												535,000	511,000	391,000
prepaid expenses and other current assets												-6,180,000	9,618,000	-5,590,000	-654,000	3,796,000	-4,518,000	-4,568,000	7,047,000	-3,284,000	-897,000	-3,704,000	-80,000	-950,000	-193,000	-759,000	8,000	-779,000	284,000	-693,000
other long-term assets												-194,000	285,000	-1,727,000	2,572,000	279,000	408,000	63,000	-4,001,000	-1,238,000	-44,000	-91,000	-609,000	56,000	-5,000	-30,000
accrued research and development												4,808,000	2,865,000	5,567,000	-10,808,000
other accrued liabilities												6,090,000	-1,758,000	-8,462,000	5,056,000	4,919,000	2,170,000	-2,007,000
operating lease liabilities												-1,727,000	-1,276,000	92,000	117,000	-402,000	-398,000	-605,000
other long-term liabilities												1,069,000	375,000	2,270,000	-496,000	0	0	-2,000	2,228,000	7,663,000
purchases of short-term and long-term investments												-322,261,000	-385,558,000	-377,573,000	-134,015,000	-214,160,000	-178,292,000	-192,398,000	-170,755,000	-429,214,000	-130,804,000	-8,885,000	-67,510,000	-56,408,000	-51,430,000	-72,407,000	-39,485,000	-131,396,000
proceeds from maturities of short-term and long-term investments												228,036,000	169,007,000	93,817,000	117,934,000	133,407,000	187,368,000	251,365,000	172,043,000	43,166,000	42,984,000	49,150,000	55,602,000	87,322,000	78,654,000	87,314,000	42,254,000
sales of short-term and long-term investments												116,239,000	8,368,000	18,484,000	43,501,000	0	0	7,500,000
repurchase of unvested shares of stock															0	0			-5,000	-16,000	0	-33,000		-43,000	-46,000	-5,000
net increase in cash and cash equivalents													-276,154,000	400,869,000		-141,050,000	-68,761,000	218,630,000		-63,336,000	217,859,000	9,389,000
share of income from equity method investee																				0	131,000	482,000	0	358,000	413,000	431,000	323,000	186,000	151,000	226,000
amounts owed by pact pharma
other current liabilities																							15,000	13,000	15,000	14,000	10,000	13,000	11,000	9,000
deferred rent																				1,007,000	-137,000	-129,000	-141,000	-135,000	-135,000	-127,000	-124,000	-120,000	-139,000	-85,000
unpaid portion of financing costs included in accounts payable
amortization of right-of-use assets																584,000	579,000	538,000
supplemental disclosures:
cash paid for amounts included in measurement of lease liabilities																1,074,000	1,073,000	927,000
cash received from tenant improvement allowances
right-of-use assets obtained in exchange for new operating lease liabilities																0
recognition of tenant improvement allowance receivable included in other current assets
unpaid portion of financing costs included in accrued liabilities
accrued research and development expenses																	5,733,000	4,716,000	-9,930,000	14,338,000
tenant improvement allowance receivable included in other current assets
vesting of early exercised stock options																	175,000	183,000
unpaid portion of deferred financing costs included in accounts payable
proceeds from issuance of common stock to related party																		220,235,000
share of loss (gain on deemed sale) from equity method investee
other non-operating income																											0	0	-118,000	-59,000
sales of short-term investments																			0	0
proceeds from initial public offering, net of issuance costs																											0	-3,000	-1,145,000	126,259,000
payment of preferred stock issuance costs																											0	0	0	-135,000
gain on deemed sale from equity method investee																				0	-131,000	-482,000					0	0
amounts owed by a related party																							0	62,000	-62,000	83,000	31,000	79,000	-139,000	-29,000
accrued liabilities																				1,824,000	13,000	648,000	-140,000	-5,890,000	7,923,000	1,606,000	-644,000	2,329,000	1,402,000	410,000
proceeds from issuance of common stock and rights to purchase additional shares, net of issuance costs
proceeds from issuance of common stock, net of issuance costs
receivable from collaboration partner
repurchase of common stock issued under early exercised options
net decrease in cash, cash equivalents and restricted cash
proceeds from issuance of common stock upon exercise of stock options, net of repurchases																								2,000			771,000	-4,000	27,000	3,304,000
net decrease (increase) in cash and cash equivalents																									7,569,000	-2,565,000
changes in operating assets and liabilities
unpaid financing cost included in accounts payable and accrued liabilities																														1,170,000
(accretion of discounts) amortization of premiums on investments
investment in related party
proceeds from issuance of preferred stock, net of issuance costs
deferred initial public offering costs
net decrease in cash and cash equivalents																											-3,825,000	-95,109,000	-28,118,000	99,690,000
cash and cash equivalents at beginning of period																											0	0	0	98,426,000
cash and cash equivalents at end of period																											-3,825,000	-95,109,000	-28,118,000	198,116,000
accretion of discounts (amortization of premiums) on investments
proceeds from maturities of short-term investments																													34,768,000	25,647,000
adjustments to reconcile net earnings to net cash from operating activities:
purchase of short-term and long-term investments																														-41,084,000
purchase of property and equipment																														-1,054,000
purchase of property and equipment purchases included in accounts payable and accrued liabilities																														695,000
vesting of early exercised options and restricted stock																														278,000

We provide you with 20 years of cash flow statements for Arcus Biosciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Arcus Biosciences stock. Explore the full financial landscape of Arcus Biosciences stock with our expertly curated income statements.

The information provided in this report about Arcus Biosciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.